TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04243837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYT-100 BCRL
Description: BCRL patients will receive LYT-100 BID for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BCRL
Description: BCRL patients will receive Placebo BID for 6 months
Study: NCT04215575

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: glaucoma implant procedure (Baerveldt)
Description: A 350 mm2 Baerveldt glaucoma implant was placed in the superotemporal quadrant in 25 patients randomized to BGI group. A limbus-based conjunctival flap was dissected, and the implant was sutured to sclera 10 mm posterior to the limbus. A scleral graft was used to cover the limbal portion of the tube, and the conjunctiva was closed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: glaucoma implant procedure (Ahmed)
Description: A 184 mm2 Ahmed glaucoma implant was placed in the superotemporal quadrant in 56 patients randomized to AGV group. A fornix-based conjunctival flap was dissected, and the implant was sutured to sclera 10 mm posterior to the limbus. The Ahmed tube left patent and viscoelastic substance injected into anterior chamber. A scleral graft was used to cover the limbal portion of the tube, and the conjunctiva was closed.
Study: NCT01753089

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: WDVAX
Study: NCT01937442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide Celgene™
Description: 200mg once daily and by mouth
Study: NCT01708837

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Propofol infusion rate is titrated to maintain the target BIS values
Study: NCT00474227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group therapy, physical exercise, nutrition lectures
Description: weekly group therapy, physical exercize, nutrition guidance
Study: NCT02395315

Intervention type: DEVICE
Intervention: Well-controlled diabetic (WC)
Description: Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.

Intervention type: DEVICE
Intervention: Poorly controlled diabetics (PC)
Description: Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
Study: NCT00565955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: Standard case management will be carried out as per guidelines given by British Thoracic Society. All patients will receive montelukast or similar looking placebo tablets. The doses of montelukast will be as follows:~5-12 years: 5 mg chewable tablet of montelukast; \> 12 years: 10 mg chewable tablet of montelukast. Study drug will be administered at time of administration of steroid.
Study: NCT02390375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-0929
Description: 5/10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DW-0929
Description: 5/10mg
Study: NCT00565955

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive placebo tablets.
Study: NCT01614457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
Study: NCT02390375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-0929
Description: 10/10mg
Study: NCT01614457

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
Study: NCT03275870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Treatment of patients with hidradenitis suppurativa with hydroxychloroquine 200mg BID for 6 months
Study: NCT02390375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DW-0929
Description: 10/10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-0929
Description: 20/10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DW-0929
Description: 20/10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 5mg F/U study: DW-0929 5/10mg
Study: NCT04244825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-2660
Description: BLD-2660 - 150 mg capsules '00' size (PO) BID
Study: NCT02390375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 10mg F/U study: DW-0929 10/10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 20mg F/U study: DW-0929 20/10mg
Study: NCT02673385

Intervention type: OTHER
Intervention: Brazelton scale
Study: NCT00066170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem
Description: Xyrem oral solution at 6 g/day for 4 weeks and 9 g/day for another 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem
Description: Xyrem oral solution at 6 g/day for 4 weeks and 9 g/day for another 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xyrem Placebo
Description: Xyrem Placebo oral solution 12 ml per day for 4 weeks and 18 ml per day for another 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xyrem Placebo
Description: Xyrem Placebo oral solution 12 ml per day for 4 weeks and 18 ml per day for another 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil at established dose
Description: Modafinil oral capsules at 200 to 600 mg per day for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil at established dose
Description: Modafinil oral capsules at 200 to 600 mg per day for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil (Placebo)
Description: Modafinil Placebo oral capsules 1 to 3 capsules per day for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil (Placebo)
Description: Modafinil Placebo oral capsules 1 to 3 capsules per day for 8 weeks.
Study: NCT04244825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-2660
Description: BLD-2660 - 150 mg capsules '00' size (PO) BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-2660
Description: BLD-2660 - 150 mg capsules '00' size (PO) BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-2660
Description: BLD-2660 - 150 mg capsules '00' size (PO) BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Placebo
Description: Placebo - 150 mg capsules '00' size (PO) BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Placebo
Description: Placebo - 150 mg capsules '00' size (PO) BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Placebo
Description: Placebo - 150 mg capsules '00' size (PO) BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Placebo
Description: Placebo - 150 mg capsules '00' size (PO) BID
Study: NCT03770975

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: delayed implant with immediate provisionaliztion and soft tissue graft
Description: delayed implant placement in the esthetic zone with immediate provisinalization and placement of a connective tissue graft buccal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed implant placement with immediate provisionalization
Description: delayed implant placement with immediate provisionalization
Study: NCT06511388

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT00283829

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Description: chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: IL2
Description: immunotherapy
Study: NCT03398109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized toric IOL for post-DALK atigmatism
Study: NCT04479384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy - osteopathic techniques
Description: * HVLAT if any somatic dysfunction in T1-T5~* Stretch intrathoracic fascia x 3~* Recoil sternum x 3~* Cranial base release, 4 phases
Study: NCT00902525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-Ibritumomab Tiuxetan
Description: All patients receive 2 courses of age-adjusted R-miniDHAP followed by two doses of 90Y-Ibritumomab Tiuxetan
Study: NCT00640432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: 75 mg oral capsule twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg oral capsule followed by 200 mg oral capsule with the evening meal (\>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days
Study: NCT02263690

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group Drops
Description: The patients in the group Drops received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. The patients in the group Drops received a second drop of proparacaine 0.5% 5 minutes after the drop of povidone iodide 5%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group SC
Description: The patients in the group SC received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. In the patients in the group SC, a subconjunctival bleb of anesthesia was created by injecting 0,4 mL of lidocaine 1% into the subconjunctival space 4 mm posterior to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-mL syringe.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group gel
Description: For the patients in group gel, the gel was placed on the eye before receiving the peri-ocular drop of povidone iodide 5%.
Study: NCT03833258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation with no precautions
Description: Patients will recover from total hip replacement surgery being guided by pain only and not by the precautions imposed upon them by clinicians.
Study: NCT04225520

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac resynchronization therapy ON
Description: Implantation of a CRT device. Bi-ventricular pacing will be turned ON.
Study: NCT00581503

Intervention type: DEVICE
Intervention: diagnostic
Description: oct imaging
Study: NCT04225520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy ON
Description: Implantation of a CRT device. Bi-ventricular pacing will be turned ON.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy OFF
Description: Implantation of a CRT device. Bi-ventricular pacing will be turned OFF.
Study: NCT01380899

Intervention type: PROCEDURE
Intervention: Biopsy of skin
Description: Under local anesthesia with 1% xylocaine, 4-mm punch biopsies with 3-mm depth, including the dermis and subcutaneous fat tissue, will undergone from two regions, neck and lower back.
Study: NCT00159484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO906, celecoxib
Description: EPO906 IV, every three weeks, celecoxib by mouth twice a day every day
Study: NCT00367809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MSBR)
Description: Mindfulness-Based Stress Reduction (MBSR) is the intervention of primary interest. It is a psycho-educational program of 8-weekly classes, 2.5 hours long taught by a trained instructor. Over the course of the program participants receive training in several formal meditation techniques: a body-scan meditation, sitting meditation, walking meditation and mindful Hatha yoga that involves simple stretches and movements. Participants are requested to practice meditation at home and to integrate informal mindfulness practices into their daily lives. The content of MBSR is described in the book Full Catastrophe Living by Jon Kabat-Zinn.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (HE)
Description: The active control condition was a peer-led chronic disease self-management program comprised of 8 weekly, 2.5 hour meetings. Led by trained peer-leaders, groups of participants discussed health challenges and problem-solved using a technique called action-planning. The curriculum described by Lorig and colleagues in the book Living a Health Life was the core of this program, and transplant-specific issues were covered in two meetings to match MBSR for time and attention.

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Delayed Intervention
Description: A temporary wait-list control group; after 6 months, those in the Delayed Intervention were randomized a second time, to one of the active treatment arms (MBSR or HE).
Study: NCT04410302

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of tumor tissue, blood, saliva, and urine samples
Study: NCT01836315

Intervention type: OTHER
Intervention: Observational Study

Intervention type: OTHER
Intervention: Observational Study
Study: NCT02924792

Intervention type: DEVICE
Intervention: Reinfusion - Sternal IO needle

Intervention type: DEVICE
Intervention: Reinfusion - Sternal IO needle

Intervention type: DEVICE
Intervention: Reinfusion - Intravenous needle
Study: NCT01006356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone HCl OROS
Description: Hydromorphone HCl OROS 8 mg once daily for 2 weeks.
Study: NCT04087499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: acupuncture treatment on selected acupoint
Study: NCT01663987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium bromide
Description: 18 mcg once a day (QD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once a day (QD)
Study: NCT01870037

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PBS-20% sucrose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hMaxi-K
Description: Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hMaxi-K
Description: Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)
Study: NCT04087499

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: acupuncture treatment on selected acupoint
Study: NCT03838705

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hypoxia
Description: It was accepted that hypoxia developed in patients with SpO2\< 92 or falling over 20% compared to preoperative values.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: normooxy
Description: It was accepted that patients with SpO2 between 100-92 mmHg
Study: NCT04055649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt/ERK Inhibitor ONC201
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02691273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cellular application treating diabetes using breathing technique
Study: NCT01501513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-3350 based bowel preparation
Description: solution for oral administration prior to colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI800 approved preparation regimen
Description: solution for oral administration prior to colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI800 investigational preparation regimen
Description: solution for oral administration prior to colonoscopy
Study: NCT01836822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS guided transbronchial forceps biopsy (EBUS-TBFB)
Study: NCT00728338

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexenoic acid (DHA)
Description: The DHA group received 7.5 g/d DHA oil (DHA 3.0 g/d) which is produced in the microalga Crypthecodinium cohinii.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: 7.5 g olive oil/day
Study: NCT02242279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01836822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS guided transbronchial needle aspiration (EBUS-TBNA)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: large bore (19G) histologic needle biopsy of the mediastinal lymph nodes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL)
Study: NCT03331211

Intervention type: DRUG
Intervention: TKIs
Description: Dasatinib combined with Chematherapy
Study: NCT02261623

Intervention type: DEVICE
Intervention: WallFlex™ Biliary RX Fully Covered Stent System RMV
Description: For use in the palliative treatment of biliary strictures produced by malignant neoplasms, and for treatment of benign biliary strictures
Study: NCT01836822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial forceps biopsy
Study: NCT01684592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-based postpartum continuing care
Description: PPCC Counselors will make initial contact with participants in the experimental group at 36 weeks gestation (i.e., one week prior to full-term), will call again within one week after the baby's birth, and eight additional times over the course of the first six months postpartum. The PPCC protocol will be developed based on the 5 A's (standard of care during pregnancy) and the Recovery Management Checkup model where relapse is expected and efforts are made to take a more proactive approach to identify women who are having cravings or have relapsed and re-intervene with them as soon as possible to assist them in regaining smoking abstinence. Women in the experimental group will also have the option of calling the PPCC line 24 hours a day, 7 days a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: All women will receive the standard of care approach (5 A's and referral to a 24/7 quit line postpartum) from MWC during pregnancy. The 5 A's brief intervention was modified by American College of Obstetricians and Gynecologists (ACOG) for use with pregnant women and is recommended to help pregnant women quit smoking. It includes the following steps: Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, and Arrange follow-up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: All women will receive the standard of care approach (5 A's and referral to a 24/7 quit line postpartum) from MWC during pregnancy. The 5 A's brief intervention was modified by American College of Obstetricians and Gynecologists (ACOG) for use with pregnant women and is recommended to help pregnant women quit smoking. It includes the following steps: Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, and Arrange follow-up.
Study: NCT02487485

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: . Subjects will receive an infusion of ketamine (0.5 mg/kg infusion over approximately 40 minutes). All subjects will receive two ketamine infusions-once with a placebo and once with a single dose of sirolimus (6 mg, oral administration).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: . Subjects will receive an infusion of ketamine (0.5 mg/kg infusion over approximately 40 minutes). All subjects will receive two ketamine infusions-once with a placebo and once with a single dose of sirolimus (6 mg, oral administration).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sirolimus
Description: Subjects will receive a single 6 mg oral dose via oral solution of sirolimus or a dose of placebo approximately two hours prior to the infusions. As above, the order of placebo and sirolimus is randomized. The sirolimus dose as well as the placebo solution will be given in 6 ounces of orange juice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Subjects will receive a single 6 mg oral dose via oral solution of sirolimus or a dose of placebo approximately two hours prior to the infusions. As above, the order of placebo and sirolimus is randomized. The sirolimus dose as well as the placebo solution will be given in 6 ounces of orange juice.
Study: NCT02261623

Intervention type: DEVICE
Intervention: WallFlex™ Biliary RX Partially Covered Stent System
Description: For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

Intervention type: DEVICE
Intervention: WallFlex™ Biliary RX Partially Covered Stent System
Description: For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

Intervention type: DEVICE
Intervention: WallFlex™ Biliary RX Partially Covered Stent System
Description: For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

Intervention type: DEVICE
Intervention: WallFlex™ Biliary RX Partially Covered Stent System
Description: For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

Intervention type: DEVICE
Intervention: WallFlex™ Biliary RX Uncovered Stent System
Description: For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

Intervention type: DEVICE
Intervention: WallFlex™ Biliary RX Uncovered Stent System
Description: For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

Intervention type: DEVICE
Intervention: WallFlex™ Biliary RX Uncovered Stent System
Description: For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
Study: NCT02487485

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral dose
Study: NCT02261623

Intervention type: DEVICE
Intervention: WallFlex™ Biliary RX Uncovered Stent System
Description: For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
Study: NCT03762980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral training (BAT)
Description: Each group received bilateral training) for upper extremities for 3 days per week for 01 hour/day for up to 6 weeks. Tasks included functional tasks such as stacking cones and cups, positioning the cup upright, throw a ball into basket, carrying a wooden block and buttoning and unbuttoning of shirt with counting. Each task was performed for 10 minutes and had a rest break of 1 minute.
Study: NCT00819195

Intervention type: DRUG
Intervention: Glatiramer acetate
Description: 20 mg daily subcutaneous injection. Six-month duration.